Protalix BioTherapeutics, Inc. (PLX) |
|
2.14 0.05 (2.39%)
|
06-01 16:00 |
|
Open: |
2.11 |
Pre. Close: |
2.09 |
|
High:
|
2.22 |
Low:
|
2.08 |
|
Volume:
|
1,276,710 |
Market Cap:
|
145(M) |
|
|
|
Technical analysis |
as of: 2023-06-01 4:46:13 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 3.41 One year: 4.14 |
| Support: |
Support1: 1.89 Support2: 1.58 |
| Resistance: |
Resistance1: 2.91 Resistance2: 3.54 |
| Pivot: |
2.22  |
| Moving Average: |
MA(5): 2.07 MA(20): 2.45
MA(100): 2.05 MA(250): 1.48 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 14.4 %D(3): 9.5 |
| RSI: |
RSI(14): 43.8 |
| 52-week: |
High: 3.54 Low: 1 |
| Average Vol(K): |
3-Month: 2,148 (K) 10-Days: 2,008 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PLX ] has closed above bottom band by 40.5%. Bollinger Bands are 46.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 22 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.22 - 2.23 |
2.23 - 2.24 |
|
Low:
|
2.05 - 2.07 |
2.07 - 2.08 |
|
Close:
|
2.12 - 2.14 |
2.14 - 2.16 |
|
Company Description |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey. |
Headline News |
Fri, 02 Jun 2023
Zacks Small Cap Weighs in on Protalix BioTherapeutics, Inc.'s Q4 ... - Defense World
Thu, 01 Jun 2023
Premarket Mover: Protalix Biotherapeutics Inc (PLX) Up 1.44% - InvestorsObserver
Tue, 30 May 2023
PLX: Back of the Envelope - Yahoo Finance
Tue, 30 May 2023
Protalix BioTherapeutics Issues Letter to Stockholders - Yahoo Finance
Tue, 23 May 2023
Protalix BioTherapeutics set to join Russell 3000® Index - Yahoo Finance
Mon, 22 May 2023
Protalix Biotherapeutics Inc (PLX) Up 1.96% in Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
